Olaparib (AZD2281, Ku-0059436)

Catalog No.S1060

Olaparib (AZD2281, Ku-0059436) Chemical Structure

Molecular Weight(MW): 434.46

Olaparib (AZD2281, KU0059436) is a selective inhibitor of PARP1/2 with IC50 of 5 nM/1 nM in cell-free assays, 300-times less effective against tankyrase-1.

Size Price Stock Quantity  
In DMSO USD 91 In stock
USD 70 In stock
USD 150 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 92 Publications

18 Customer Reviews

  • CYREN does not regulate repair of replication-induced DSBs. Representative images of chromosomes.

    Nature, 2017, 549(7673):548-552. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

    Clonogenic survival of cells expressing BARD1(WT)res or BARD1(AAE)res after treatment with olaparib or MMC. Data are means ± s.d., n = 3. EV, empty vector. P values were calculated using two-way ANOVA and multiple comparisons were corrected by the Bonferroni method. ** P < 0.01.

    Nature, 2017, 550(7676):360-365. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  • a, IC50 levels of olaparib in EWS–FLI1 mutant cells (n = 17) versus breast cancers (n = 13) or pan-cancer (n = 147) dataset. b, Cell viability of IMR90 and Ewing sarcoma cells with increasing doses of olaparib. Mean ± s.d., n = 3 technical replicates, one-way ANOVA compared to IMR90 cells. c, Cell viability plot demonstrating the role of EWS–FLI1 in mediating exquisite sensitivity to olaparib in U2OS cells transfected with either the oncogene or empty vector; n = 3 transfection replicates.

    Nature, 2018, 555(7696):387-391. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

    Western blot analysis showing PARylated proteins in cells subject to the indicated PARP inhibitor treatments (5 μM Olaparib and 10 μM NU1025).

    Cell, 2018, 172(3):439-453. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  •  

    SAHA and olaparib synergistically induced apoptosis and compromised DNA repair in the sensitive HCC cells. Cells were treated with 0.5 uM SAHA, 3 uM olaparib alone or in combination for 48 hours, and protein extracts were subjected to western blot analysis with the indicated antibodies.

    Hepatology 2012 55, 1840-1851. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

     

    SAHA and olaparib synergistically induced apoptosis and compromised DNA repair in the sensitive HCC cells. Cells were treated with 0.5 uM SAHA, 3 uM olaparib alone or in combination for 48 hours, and protein extracts were subjected to western blot analysis with the indicated antibodies.

    Hepatology 2012 55, 1840-1851. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  •  

    SAHA and olaparib synergistically induced apoptosis and compromised DNA repair in the sensitive HCC cells. Cells were treated with 0.5 uM SAHA, 3 uM olaparib alone or in combination for 24 (A) or 12 (B) hours, subjected to staining with propidium iodide (A) or FITC-Annexin V (B), and then analyzed by flow cytometry.

    Hepatology 2012 55, 1840-1851. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

     

    Mechanism of FK866/olaparib synergy. FK866 exacerbates levels of gH2AX caused by olaparib. CAL51 cells were exposed to FK866 and/or olaparib for 48 h and cell lysates generated and immunoblotted for total and gH2AX.

    EMBO Mol Med 2012 4, 1087-1096. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  • Role of PARP and BER in the synergy between PTX and GMX in A549 cells. A) Cells were pre-treated +/- 1 uM olaparib (2h) then sequentially +/- 150nM PTX (24h) then +/- GMX 12nM (48h). Cells were harvested for (left) NAD+ quantification by LC-MS/MS (mean +/-SD of quadruplicates) or (right) viability by CellTiter-Glo (mean +/-SD of duplicates) B) PAR modification of proteins and γ-H2AX levels were measured in extracts treated as in A) by western blotting.

    Cancer Res 2014 74(21), 5948-54. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

    J Exp Clin Cancer Res 2013 32(1), 95. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  • (A) Representative confocal microscopy images of nuclear γ-H2AX (red) and DAPI (blue) staining in FKO1 cells 30 minutes following irradiation. Cells pre-treated for 24hr with 1μM NanoOlaparib, olaparib, or a vehicle control before irradiation.

    Mol Cancer Ther, 2017, 16(7):1279-1289. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

    MSH3-deficient cells are sensitive to olaparib, a PARP inhibitor, and the combination with oxaliplatin. A, clonogenic survival of HCT11635, G5 without doxycycline (DOX), and G5 cells with doxycycline, which were treated with 2 μM of oxaliplatin, 2 μM of olaparib, and the combination of these two drugs. B, clonogenic survival of HT29 cells, which were treated with 1 μM oxaliplatin, 2 μM olaparib, and the combination of these two drugs.

     

     

    J Biol Chem 2011 286, 12157-12165. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  • Logarithmic growth curves of human Burkitt lymphoma cells over 5 days with 500 nmol/l of ABT-888 and AZD-2281 in combination with 0 Gy (a), 4 Gy (b), 8 Gy (c), and 12 Gy (d) of external beam radiation. The maximal relative reduction was 65.5% of viable cells and occurred with AZD-2281 (500 nmol/l) on day 5. DMSO, dimethyl sulfoxide.

    Nucl Med Commun 2011 32, 1046-51. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

    Nucl Med Commun 2011 32, 1046-51. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  •  

    Number of foci detected using laser confocal microscopy and fluorescent Fluor 647 anti-H2A.X-phosphorylated (Ser139) antibody. Double-stranded breaks (red) are clearly augmented in cells incubated with 500 nmol/l of ABT-888 and 500 nmol/l of AZD-2281 compared with PBS and 1% dimethyl sulfoxide controls. Image analysis was performed using ImageJ and the ‘analyze particle’ function.

    Nucl Med Commun 2011 32, 1046–1051 . Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

    Olaparib inhibited cell proliferation, and CRC cells with high XRCC2 expression had higher olaparib sensitivity. The surviving fractions of SW480 cells treated with (A) 1 mM, (B) 10 mM, and (C) 50 mM olaparib were measured using CCK-8. (D) The relation between cell viability and olaparib concentration.

    Medicine (Baltimore) 2014 93(28), e294. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  • in vivo suppression of PAR formation by the PARP inhibitor AZD2281 upon induction of DNA damage Primary human lung fibroblast cells (MRC-5) were pre-treated with the indicated concentration of the PARP inhibitor AZD2281 for two hours. Oxidative DNA damage was induced by 500 µM H2O2 for 10 min and cellular PARP activity was measured by immuno-staining of poly(ADP)-ribose (PAR) (right panels). The in vivo effect of PARP inhibition was compared to cells without DNA damage induction and inhibitor (control) and H2O2-treated cells without inhibitor. Average nuclear PAR staining intensities of more than 50 cells were statistically analysed by Kruskal-Wallis and the post-hoc Dunn’s Multiple Comparison tests (left panel). Asterisks indicate highly significant (p<1%) differences to H2O2-treated cells without PARP inhibitor. Thick horizontal bars mark medians and error bars the interquartile range.

    2010 Dr. David Schrmann from University of Base. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

    Effect of AZD 2281 on the viability of endometrial cancer cell line Hec50 and Ishikawa and ovarian cancer cell line SKOV3,Caov3 and PA-1 was detected by WST-1 method after 3 days treatment.

     

     

    2010 Dr. Xiangbing Meng of University of Iowa. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

Purity & Quality Control

Choose Selective PARP Inhibitors

Biological Activity

Description Olaparib (AZD2281, KU0059436) is a selective inhibitor of PARP1/2 with IC50 of 5 nM/1 nM in cell-free assays, 300-times less effective against tankyrase-1.
Features A potent PARP inhibitor (currently in late stage clinical trials).
Targets
PARP2 [1]
(Cell-free assay)
PARP1 [1]
(Cell-free assay)
1 nM 5 nM
In vitro

Olaparib would act against BRCA1 or BRCA2 mutations. Olaparib is not sensitive to tankyrase-1 (IC50 >1 μM). Olaparib could ablate the PARP-1 activity at concentrations of 30-100 nM in SW620 cells. Olaparib is hypersensitive to BRCA1-deficient cell lines (MDA-MB-463 and HCC1937), compared with BRCA1- and BRCA2-proficient cell lines (Hs578T, MDA-MB-231, and T47D). [1] Olaparib is strongly sensitive to KB2P cells due to suppression of base excision repair by PARP inhibition, which may result in the conversion of single-strand breaks to double-strand breaks during DNA replication, thus activating BRCA2-dependent recombination pathways. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
KP3.33 NHTRSYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWW0JIQ> M2TEW2lEPTB;NT63NFUhKM7:TTC= M3e2cVE5PTV7NkGz
KP6.3 M1vONGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUmwSXZOPCCm MXnJR|UxRTFyLkSyPEDPxE1i MWSxPFU2QTZzMx?=
KP7.7 M1j3[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVG4T3JlPCCm NIHlO5VKSzVyPUW3JI5OKA>? MXyxPFU2QTZzMx?=
KB2P3.4 MmfDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\nXWQ1KGR? MVHJR|UxRTF{NDDNJC=> M33GflE5PTV7NkGz
KB2P1.21 NWjpN5FZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXW0JIQ> MV7JR|UxRTh7MEegcm0h NXfoN4hROTh3NUm2NVM>
U373-MG MVfDfZRwfG:6aXOgRZN{[Xl? NYLmOJNWOSEQvF2g NXrNPVZYOjRiaB?= NWnVVmZ7UW6lcnXhd4V{KHKjZHnheIlwdiC|ZX7zbZRqfmm2eR?= M{HqTFE5QTV2N{Gy
T98G M2PsUmN6fG:2b4jpZ{BCe3OjeR?= M1jqd|Eh|ryPIB?= Mk\UNlQhcA>? M{KyVWlv[3KnYYPld{Bz[WSrYYTpc44he2Wwc3n0bZZqfHl? NFTKN5IyQDl3NEexNi=>
U87-MG Mn\OR5l1d3SxeHnjJGF{e2G7 NIHyc4EyKM7:TTC= Ml\XNlQhcA>? M4n6bGlv[3KnYYPld{Bz[WSrYYTpc44he2Wwc3n0bZZqfHl? M3[1dVE5QTV2N{Gy
UVW M1nHcmN6fG:2b4jpZ{BCe3OjeR?= M4rqe|UxOCCwTR?= NYj5[ZlWOjRiaB?= MkjpTY5kemWjc3XzJJJi\GmjdHnvckB{\W6|aYTpeol1gQ>? Mn60NVg6PTR5MUK=
HeLa NXK0VJBSTnWwY4Tpc44hSXO|YYm= MnXhOVAxKG6P NI\lfZQ1KGh? NXXuS21{S2G3c3XzJIEhdW:mZYP0JIRmdGG7IHnuJJJmcm:rbnnu[{Bw\iC{YXTpZZRqd25vaX7keYNm\CCGTlGgZpJm[Wu| NGXreVUyQDl3NEexNi=>
HeLa NW\BZ2lVTnWwY4Tpc44hSXO|YYm= M4jsUlEh|ryPIB?= MYSyOEBp NF:wZWlGdmijbnPld{Bz[WSrYYTpc44ucW6mdXPl[EBUNXCqYYPlJIFzemW|dB?= NFHI[XoyQDl3NEexNi=>
T98G NWOxOnlpTnWwY4Tpc44hSXO|YYm= NIPDbo0yKM7:TTC= NVrTRpVpOjRiaB?= Mk\PSY5p[W6lZYOgdoFlcWG2aX;uMYlv\HWlZXSgV{1xcGG|ZTDhdpJme3R? M1;GNFE5QTV2N{Gy
L3 NVz4d45jS3m2b4TvfIlkKEG|c3H5 NEDX[2U2KM7:TTC= MWK5OkBp M4OzR2ROW09? NHvafWRUcWewaX\pZ4FvfGy7IHnubIljcXS|IHPlcIwhe3W{dnn2ZYw> NHLPRmQzODF{NES1PS=>
Granta-519 NFz0SW1EgXSxdH;4bYMhSXO|YYm= MUC1JO69VSB? MU[5OkBp NWTON5N1TE2VTx?= Ml\DV4xq\2i2bImgbY5pcWKrdIOgZ4VtdCC|dYL2bZZidA>? NYDaXYhkOjBzMkS0OVk>
BT NX23Wo1OS3m2b4TvfIlkKEG|c3H5 M17OWFUh|ryPIB?= NF\abmI6PiCq M1\4e2ROW09? M4Xk[3NtcWeqdHz5JIlvcGmkaYTzJINmdGxic4Xyeol3[Wx? MWmyNFEzPDR3OR?=
UPN2 MXfDfZRwfG:6aXOgRZN{[Xl? NU\mTlRLPSEQvF2g MXO5OkBp M{HkbmROW09? NFHUbIlUdGmpaITsfUBqdmirYnn0d{Bk\WyuIIP1dpZqfmGu NVjBSnlDOjBzMkS0OVk>
HBL-2 M{HQNGN6fG:2b4jpZ{BCe3OjeR?= MlX0OUDPxE1i NXfMcJBkQTZiaB?= NI\QUGdFVVOR MVnTcIlocHSueTDpcohq[mm2czDj[YxtKHO3co\peoFt NHHvOIkzODF{NES1PS=>
JVM-2 NGqzWYNEgXSxdH;4bYMhSXO|YYm= MkP0OUDPxE1i NW\LVnBOQTZiaB?= M2fmbWROW09? NH3HNFFUdGmpaITsfUBqdmirYnn0d{Bk\WyuIIP1dpZqfmGu Mn;XNlAyOjR2NUm=
Z138 M{T3NGN6fG:2b4jpZ{BCe3OjeR?= Mn36OUDPxE1i NHnJOVY6PiCq MYPEUXNQ MkniV4xq\2i2bImgbY5pcWKrdIOgZ4VtdCC|dYL2bZZidA>? NG\XTWkzODF{NES1PS=>
RWPE MWTJcpZie2m4ZTDBd5NigQ>? MYSyOUDPxE1? MX60PEBp MnXGSG1UVw>? MVvTbYdvcW[rY3HueIx6KHKnZIXj[ZMhTVKJLXTybZZmdiClZXzsJIlvfmG|aX;u MXSyNVU4PTh4NR?=
VCaP NV7RXHBYUW64YYPpeoUhSXO|YYm= NEPNWIMzPSEQvF2= MYm0PEBp M3LOZ2ROW09? NWj2eJIzW2mpbnnmbYNidnSueTDy[YR2[2W|IFXSS{1lemm4ZX6gZ4VtdCCrbo\hd4lwdg>? MXyyNVU4PTh4NR?=
Mouse H2AX−/− ES Cells MlLiR5l1d3SxeHnjJGF{e2G7 M{XSb|IvPSEQvF2= NVrSdW4yOjBiaB?= M1n2dHNq\26rZnnjZY51dHliaX7obYJqfHNiY3XscEB{fXK4aY\hcC=> MUiyN|M2PTR6OR?=
Mouse ATM−/− ES Cells NWnQPYZ4S3m2b4TvfIlkKEG|c3H5 MVqyMlUh|ryP M2jN[lIxKGh? Moj4V4lodmmoaXPhcpRtgSCrbnjpZol1eyClZXzsJJN2en[rdnHs MkPpNlM{PTV2OEm=
H1650 M{joWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3OyUFIxKM7:TR?= MXuxOFQhcA>? NGP3[21KSzVyPUG1MlQ4KM7:TR?= NFrUZ28zOzJ|OUiwPS=>
H1650PTEN+ NIfY[W5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjvNlAh|ryP NVvLb5g5OTR2IHi= MUXJR|UxRTVyLkizJO69VQ>? NUP4WFdsOjN{M{m4NFk>
PC-9 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVeyNEDPxE1? Ml:yNVQ1KGh? NHfVTJNKSzVyPUWuPFgh|ryP MYOyN|I{QThyOR?=
PC-9PTEN− M1TQPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXWyNEDPxE1? NXLVPZNWOTR2IHi= NIfi[nFKSzVyPU[uOVIh|ryP Ml\ONlMzOzl6MEm=
MDA-MB-231 MlnaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3f1VFUh\GG7 NULFXFlWUUN3ME22Mlkh|ryP MWWyN|c3ODR7Nh?=
MDA-MB-468 M4PVfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\rOVI2KGSjeR?= NFrVPI9KSzVyPUWuNEDPxE1? MViyN|c3ODR7Nh?=
BT20 NE\XZVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;NVVUh\GG7 M33mTmlEPTB;Nz63JO69VQ>? Mof1NlM4PjB2OU[=
HCC1143 M2fiS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVW1JIRigQ>? NVvsWFF2UUN3ME2xNU4yKM7:TR?= M{HPflI{PzZyNEm2
HCC1937 MlPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVzQb2ZtPSCmYYm= MkfzTWM2OD1zMj62JO69VQ>? M3TE[lI{PzZyNEm2
Hs578t M4DBUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYe1JIRigQ>? MUPJR|UxRTVwNjFOwG0> MnrzNlM4PjB2OU[=
Hs578t(si) MoHZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFvMb3M2KGSjeR?= NWr0cI92UUN3ME23MlUh|ryP Mn;ONlM4PjB2OU[=
BT474 M17MV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHzrcmk2KGSjeR?= MXPJR|UxRTF7Lkig{txO NX60S4NQOjN5NkC0PVY>
JIMT1 NHn1fm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFLxXY82KGSjeR?= NEDQXXRKSzVyPUeuO{DPxE1? NX\Wc3VuOjN5NkC0PVY>
SKBR3 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVi1JIRigQ>? NWrKfVd7UUN3ME2xNU4yKM7:TR?= MkfUNlM4PjB2OU[=
SUM159 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{HKNlUh\GG7 NUPkdlg3UUN3ME20MlIh|ryP MVmyN|c3ODR7Nh?=
CAMA1 MljmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTodZE2KGSjeR?= NIfX[oVKSzVyPUG1Mlgh|ryP MVWyN|c3ODR7Nh?=
MCF7 Ml\XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\Qe|Uh\GG7 NYrIZZVWUUN3ME21Mlgh|ryP M3jaWVI{PzZyNEm2
T47D NEGy[3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUK1JIRigQ>? Ml\kTWM2OD17Lk[g{txO M3nCd|I{PzZyNEm2
HCT116 M3fTVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnnzNVAxKM7:TR?= NUn5eJA3PDhiaB?= NGS3RZdFVVOR MXPJR|UxRTJwNTFOwG0h M1nCRlI1PTd5OUSx
SW1116 M3P3SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\YOVRNOTByIN88US=> MljtOFghcA>? MoPrSG1UVw>? NWLPT3JtUUN3ME2xNFAh|ryP NIf4VJIzPDV5N{m0NS=>
HT29 NEHERo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfHO4w2OTByIN88US=> MVe0PEBp NEXiZ2FFVVOR NFzHNW5KSzVyPUG0Mlch|ryP Mkn3NlQ2Pzd7NEG=
LoVo MkXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3Tob|ExOCEQvF2= Ml\SOFghcA>? MmjuSG1UVw>? NHnyeGtKSzVyPUGzMlQh|ryP NHS1TGMzPDV5N{m0NS=>
HCT-15 NWDmS3hJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGf2XIUyODBizszN M3H5c|Q5KGh? MX3EUXNQ M4TIeGlEPTB;MUCg{txO Mor4NlQ2Pzd7NEG=
SW48 NEPkTHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVz5Z3gzOTByIN88US=> NWPhVHlSPDhiaB?= M2Xkd2ROW09? Mnv0TWM2OD17LkWg{txO MmPiNlQ2Pzd7NEG=
C-1 M3XrT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2HSTFExOCEQvF2= M{DsUFQ5KGh? NEDQdnBFVVOR M2TCZWlEPTB;Nz62JO69VQ>? MonrNlQ2Pzd7NEG=
RKO MkjrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVSxNFAh|ryP NUK1VZdiPDhiaB?= M3juXGROW09? NEXsXI9KSzVyPUWuPUDPxE1? NUD5NGd7OjR3N{e5OFE>
HCT116 NGOydoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LqUVExOCEQvF2= M2HRU|Q5KGh? NIjh[5JFVVOR M{PpdHBwfGWwdHnheIV{KFOQLUO4JIN6fG:2b4jpZ4l1gSB? M1XVWFI1PTd5OUSx
SW1116 M3rvSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\tVFYyODBizszN M2DQOlQ5KGh? Mn\DSG1UVw>? NYDTb|V7WG:2ZX70bYF1\XNiU16tN|gh[3m2b4TvfIlkcXS7IB?= MWCyOFU4Pzl2MR?=
HT29 M2X4fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlPMNVAxKM7:TR?= M3;ZRlQ5KGh? Ml\GSG1UVw>? MmDsVI91\W62aXH0[ZMhW05vM{igZ5l1d3SxeHnjbZR6KA>? M3LW[|I1PTd5OUSx
LoVo NEDNeIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoHPNVAxKM7:TR?= M1rUOVQ5KGh? NXu3PIM5TE2VTx?= NVOzPY1uWG:2ZX70bYF1\XNiU16tN|gh[3m2b4TvfIlkcXS7IB?= NGC0ToEzPDV5N{m0NS=>
SW48 M4HMN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWnBT49kOTByIN88US=> MXq0PEBp MWrEUXNQ Ml3UVI91\W62aXH0[ZMhW05vM{igZ5l1d3SxeHnjbZR6KA>? NHqw[ngzPDV5N{m0NS=>
C-1 Mm\yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{TqeFExOCEQvF2= M4K4UVQ5KGh? MkHSSG1UVw>? M4DUdHBwfGWwdHnheIV{KFOQLUO4JIN6fG:2b4jpZ4l1gSB? MWSyOFU4Pzl2MR?=
RKO NX\qU|BET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU[xNFAh|ryP MXm0PEBp MVrEUXNQ MnfpVI91\W62aXH0[ZMhW05vM{igZ5l1d3SxeHnjbZR6KA>? MXiyOFU4Pzl2MR?=
HCT116 MVHGeY5kfGmxbjDBd5NigQ>? M3TJc|ExKG6P MlfuNVIhcA>? MlLMSG1UVw>? NFy0cYNKdmO{ZXHz[ZMhTE6DIHTveYJt\S2|dILhcoQh[nKnYXvzJIlv\HWlZXSgZpkhW05vM{i= MYGyOFU4Pzl2MR?=
HT29 NYWyXYp[TnWwY4Tpc44hSXO|YYm= NYTNcmtqOTBibl2= MmLtNVIhcA>? NUDq[3BETE2VTx?= M4XDRmlv[3KnYYPld{BFVkFiZH;1ZoxmNXO2cnHu[EBjemWja4OgbY5lfWOnZDDifUBUVi1|OB?= NWPQbpV5OjR3N{e5OFE>
TE-6 NITCXG1HfW6ldHnvckBCe3OjeR?= NIjWR4k2KM7:TTC= MorlNVIhcA>? MXzEUXNQ NXHPcGNjUW6mdXPld{BIOi:PIHHydoV{fA>? NYnDSpZYOjR{MUmxOlQ>
TE-6 NGj3T4lHfW6ldHnvckBCe3OjeR?= NWO2OGkyPSEQvF2g MVyyOEBp NYXtXIFwTE2VTx?= MYfJcoNz\WG|ZYOgbY4h\G:3YnzlJJN1emGwZDDidoVic3NiKFTTRpMq NF;sbWYzPDJzOUG2OC=>
Hep3B M{C0UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHjhb5A1OCEQvF2g NIL0e3Y4OiCq M2r5b2ROW09? NX3UeY5bW3mwZYLnbZN1cWOjbHz5JIlvcGmkaYTzJINmdGxiZ4Lve5RpKHerdHigSGhOTVF? NVLL[m4xOjVyN{K3OVI>
Huh7 MlrNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\sOFAh|ryPIB?= NYLuVHZPPzJiaB?= MXvEUXNQ NUD6VWw1W3mwZYLnbZN1cWOjbHz5JIlvcGmkaYTzJINmdGxiZ4Lve5RpKHerdHigSGhOTVF? NFi0fYszPTB5Mke1Ni=>
Hep3B NX;ENJpHTnWwY4Tpc44hSXO|YYm= NWXkUXdzPDBizszNJC=> NEi0[lMzPCCq NYHkUWZVTE2VTx?= Mm\jTY5lfWOnczDSU3MheHKxZIXjeIlwdiC5aYToJGRJVUWT NGK1ZpkzPTB5Mke1Ni=>
Huh7 MkDDSpVv[3Srb36gRZN{[Xl? M{LWelQxKM7:TTC= NHfMdoYzPCCq NWPxRWJWTE2VTx?= NYP0ZY9yUW6mdXPld{BTV1NicILv[JVkfGmxbjD3bZRpKESKTVXR NVLvOFJQOjVyN{K3OVI>
Hep3B M{jFdGZ2dmO2aX;uJGF{e2G7 NIDQdYM1OCEQvF2g NEXqUGUzPCCq M1HSVWROW09? M{Ow[Glv\HWlZYOgZ4VtdCCjdYTvdIhi\3lid3n0bEBFUE2HUR?= NGHPVnAzPTB5Mke1Ni=>
Huh7 M2HGR2Z2dmO2aX;uJGF{e2G7 Mor0OFAh|ryPIB?= MlSzNlQhcA>? NFe2S5JFVVOR M3TTe2lv\HWlZYOgZ4VtdCCjdYTvdIhi\3lid3n0bEBFUE2HUR?= M2PrVVI2ODd{N{Wy
SGC-7901 M{jlWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDnZ|Y{OMLizszN NX7TVXZvPDhiaB?= NE\Hbo1FVVOR MYnCcI9kcyCxeHHsbZBt[XSrbj3pcoR2[2WmIHPlcIwh\GWjdHi= MljPNlU4PjdyN{[=
COLO-800 M3nUUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYPqTlRjUUN3ME2wMlQ1OTZ2IN88US=> NIPGU|hUSU6JRWK=
EoL-1- MlTBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{TPOGlEPTB;MD61OlQ1PiEQvF2= NEfGWXdUSU6JRWK=
NCI-H209 MkjTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmizTWM2OD1yLkmxOVU3KM7:TR?= NVLhPW9ZW0GQR1XS
ES1 M3HXTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTFwMUG0NFgh|ryP NH3Gdo9USU6JRWK=
NKM-1 MknxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTFwMkWzOFch|ryP M1HGUHNCVkeHUh?=
NTERA-S-cl-D1 NVjpdFZJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\nTWM2OD1zLkOzN|QyKM7:TR?= M{n6bXNCVkeHUh?=
MHH-ES-1 M4HYUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnP2TWM2OD1zLk[yNFY4KM7:TR?= MnHNV2FPT0WU
ES8 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTFwN{K0NVQh|ryP MnnEV2FPT0WU
NCI-H720 MlXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVrGZ2ZvUUN3ME2yMlIxPjl7IN88US=> MlHRV2FPT0WU
EW-3 MlrJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonyTWM2OD1{LkK3OVM1KM7:TR?= NG\6[|dUSU6JRWK=
D-566MG M13zbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEOzXlJKSzVyPUKuOFQ2PjhizszN M2jTbHNCVkeHUh?=
697 NFyzVZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PCPGlEPTB;Mj64OFE4OyEQvF2= NYfnV5NGW0GQR1XS
ES5 NWr1PXlXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\YPXhKSzVyPUKuPFgyQDlizszN MVrTRW5ITVJ?
COLO-684 M3XGZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH\jU4JKSzVyPUOuOVE3QTZizszN M2T0fXNCVkeHUh?=
ML-2 MkLuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{[5SGlEPTB;Mz62NFA2QCEQvF2= M3rndnNCVkeHUh?=
MC-IXC MkHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHvHRY1KSzVyPUOuOlM{QTNizszN NFXXfYFUSU6JRWK=
DB M2nhPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTNwNkW0OFgh|ryP NGS5e5hUSU6JRWK=
HCC2218 MoXuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVHFfWduUUN3ME2zMlc{OTB|IN88US=> NILmOIdUSU6JRWK=
NCI-H510A NWDF[lZCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1PHOGlEPTB;Mz64NlczPCEQvF2= NID2OHdUSU6JRWK=
NCI-H526 MlXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\xTGlEPTB;Mz64Olk2QCEQvF2= Mm\HV2FPT0WU
MV-4-11 M3vUO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4r6SWlEPTB;ND6xN|M{PCEQvF2= NUfpPY1YW0GQR1XS
PA-1 M{LlfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PRRmlEPTB;ND6yOVI6KM7:TR?= M1zKcXNCVkeHUh?=
EW-22 MoDmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX3kSHFTUUN3ME20MlM2QDZizszN MlTiV2FPT0WU
KASUMI-1 MnfLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmjzTWM2OD12LkSwNVA6KM7:TR?= MUPTRW5ITVJ?
LU-139 NXPCSlE1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPHdo9KSzVyPUSuO|U5OjlizszN MYXTRW5ITVJ?
SBC-1 NXrVOnhzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjVTHJKSzVyPUSuPFA6ODhizszN NG\zSmJUSU6JRWK=
H4 NVfKUlRYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIPQTXJKSzVyPUSuPFk1PDNizszN NF3wVXlUSU6JRWK=
EW-11 NVrYV3I1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3znWWlEPTB;NT6wPFA4OiEQvF2= M17ZWXNCVkeHUh?=
NBsusSR NX7WSopzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIX6R3VKSzVyPUWuNVIxPTVizszN MX7TRW5ITVJ?
RPMI-8226 NFjSVopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTVwMUWyOFQh|ryP NV:zXJNIW0GQR1XS
DEL NGm1WmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUS5V|RIUUN3ME21MlIxODB4IN88US=> M{\6VHNCVkeHUh?=
ES4 M1;JNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFLYV5dKSzVyPUWuOVE{QDlizszN MX\TRW5ITVJ?
GCT NUjy[XBtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLMS5VmUUN3ME21MlU3QDV4IN88US=> M1XtZ3NCVkeHUh?=
NCI-H1048 NFzsVnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYK1NJRYUUN3ME21Mlk4Ojd|IN88US=> NITUVodUSU6JRWK=
NCI-SNU-1 M{fNbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHHfZhKSzVyPU[uNFIzKM7:TR?= Mn;HV2FPT0WU
ES7 NI\lOlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVPNb252UUN3ME22MlA{PTd5IN88US=> NUjlSIFZW0GQR1XS
SW982 M1\rWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVrP[G9FUUN3ME22MlA6OTN5IN88US=> NYPhd4xFW0GQR1XS
L-363 MkfXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvjVmxPUUN3ME22MlM{QTd2IN88US=> Mli3V2FPT0WU
HT-1080 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXm4eZF4UUN3ME22MlQ6Pjh|IN88US=> NFPrXnVUSU6JRWK=
HAL-01 NWm5TnZKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVfRVHRiUUN3ME22MlUyODlizszN MlXYV2FPT0WU
NB14 Mmq1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1TiWmlEPTB;Nj62OFA{QSEQvF2= NGnGT2FUSU6JRWK=
EW-13 M3XBOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXPPJhKSzVyPU[uO|c1OjRizszN M3zHe3NCVkeHUh?=
NY Mlq1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;TTWM2OD14Lkm0OlA2KM7:TR?= NGW5Z2FUSU6JRWK=
NCI-SNU-5 M3jkW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MorGTWM2OD15LkGwOFM{KM7:TR?= NIHNe|VUSU6JRWK=
MS-1 NYPvUXE{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTdwMUe0PVQh|ryP NWnlOHU5W0GQR1XS
EW-16 NGPMUWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NESz[3pKSzVyPUeuN|E5PjFizszN NFXSU5JUSU6JRWK=
LU-65 NEfiN45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2XkSWlEPTB;Nz60PFQyPyEQvF2= M1\2RXNCVkeHUh?=
HGC-27 NF\ONXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{PnTWlEPTB;Nz63NlE4OyEQvF2= NIDoSFRUSU6JRWK=
CTB-1 M2LJVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnrhTWM2OD15Lke2NVc2KM7:TR?= NWDtd|VKW0GQR1XS
5637 M1zlSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHEVJlNUUN3ME23MlkzQDZizszN NGDYSlRUSU6JRWK=
U251 NXLDZ2ZIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEfZTm1KSzVyPUeuPVQxOTZizszN M1q1O3NCVkeHUh?=
HOS M3PNWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn25TWM2OD16LkKzNFA4KM7:TR?= MXLTRW5ITVJ?
DOHH-2 NEHzbWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7HfoZKSzVyPUiuNlM2QCEQvF2= M3H3U3NCVkeHUh?=
EW-1 MoTNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVW3WnFQUUN3ME24MlMxODh6IN88US=> M37PZnNCVkeHUh?=
BV-173 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWPzNIU4UUN3ME24MlU2PTRizszN NXmyeJVlW0GQR1XS
8-MG-BA M1fMe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXmzPHRRUUN3ME24MlY5QTh6IN88US=> NEnlS4pUSU6JRWK=
NB69 NWDaR3o{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGnTV3FKSzVyPUiuO|A6OjFizszN NIfXXIRUSU6JRWK=
NCI-H69 NFT1c3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTlwOUC5OlEh|ryP NYr3Rm0zW0GQR1XS
RS4-11 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlLKTWM2OD1zMT6yNlA5KM7:TR?= MYPTRW5ITVJ?
ONS-76 NF71PXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVK1T|ltUUN3ME2xNU4zQTR5IN88US=> NH3DWHFUSU6JRWK=
SF539 NUDEdllCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LQfGlEPTB;MUGuOFg5QSEQvF2= MV7TRW5ITVJ?
HuO-3N1 NWX0dVRHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTFzLkW3PVYh|ryP MXjTRW5ITVJ?
NCI-H1651 M1HLdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NELUdotKSzVyPUGyMlMyOTVizszN MmHUV2FPT0WU
KARPAS-45 MmTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MorITWM2OD1zMj6zO|Yh|ryP Mk\jV2FPT0WU
SK-NEP-1 NW\LNHhbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3Gxd2lEPTB;MUKuOFYxQSEQvF2= M2HNeXNCVkeHUh?=
LAMA-84 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTF|LkGwPVUh|ryP MV\TRW5ITVJ?
NCI-H1155 MkPnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NILwbXJKSzVyPUGzMlI5PTZizszN Mnn5V2FPT0WU
CTV-1 NYrvbGNST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTF|LkS0OUDPxE1? MlL2V2FPT0WU
QIMR-WIL MmX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGf0RYpKSzVyPUGzMlc5OTRizszN M3qyeXNCVkeHUh?=
H9 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVz2eopCUUN3ME2xN{45PDd3IN88US=> NG\IZ2pUSU6JRWK=
SK-MEL-1 M12xNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTJTWM2OD1zMz65N|Q4KM7:TR?= MkTJV2FPT0WU
HD-MY-Z M{fDXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXrwcpl5UUN3ME2xOE4xPjN5IN88US=> NIHwW3FUSU6JRWK=
TI-73 NITueXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlHVTWM2OD1zND6yN|U3KM7:TR?= MV3TRW5ITVJ?
JVM-3 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmrOTWM2OD1zNT61O|E3KM7:TR?= M2[yeXNCVkeHUh?=
D-247MG MkjFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\tTWM2OD1zNT61PVMh|ryP NIDzcZVUSU6JRWK=
VA-ES-BJ M33q[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTF3Lk[wPVch|ryP M1L3UHNCVkeHUh?=
NOS-1 NFnsS|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWOxeJlGUUN3ME2xOU43PTJ{IN88US=> M1q1WXNCVkeHUh?=
MOLT-4 Mm\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVS2XIQ6UUN3ME2xOk44PTJizszN MkDPV2FPT0WU
Mo-T Mnr0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVK3fGlNUUN3ME2xO{4xQDR7IN88US=> NIPlcolUSU6JRWK=
NCI-H1770 NGCw[mVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHuOVdKSzVyPUG3MlE2PDNizszN NELte25USU6JRWK=
COLO-320-HSR MknhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTF5LkG4Nlch|ryP NGDMbodUSU6JRWK=
TE-12 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWTDW5V3UUN3ME2xO{44ODV2IN88US=> NF;iWpRUSU6JRWK=
NCI-H82 NWTSemwxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYjXe3JCUUN3ME2xO{45PzJ6IN88US=> NYroVphOW0GQR1XS
NEC8 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{LCOmlEPTB;MUiuNVMyPiEQvF2= Mo\wV2FPT0WU
HSC-3 Mn\XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NESzUmdKSzVyPUG4Mlc1OTRizszN NXztTYJ1W0GQR1XS
NCI-H1092 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTF6Lke1PVUh|ryP M1rvZnNCVkeHUh?=
NCI-H292 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn3lTWM2OD1zOT6wOFg6KM7:TR?= MWTTRW5ITVJ?
L-428 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHvid2ZKSzVyPUG5MlU2QSEQvF2= NIHsTWlUSU6JRWK=
LU-134-A MmjkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTF7LkW3NkDPxE1? Mn:4V2FPT0WU
GI-ME-N NGDiXG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1S0V2lEPTB;MUmuOVc1PyEQvF2= MUDTRW5ITVJ?
ALL-PO NVnGOJpqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXrFUmR{UUN3ME2xPU42QTd{IN88US=> NGrTbItUSU6JRWK=
D-283MED M1rmSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2PhXmlEPTB;MUmuPVE2KM7:TR?= M4HCdXNCVkeHUh?=
D-423MG MoTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jD[2lEPTB;MUmuPVk3PyEQvF2= NX3yXYd7W0GQR1XS
CAKI-1 M1zOSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTJyLkKyNVkh|ryP NIOyTYtUSU6JRWK=
ETK-1 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4[1dWlEPTB;MkCuNlYyPSEQvF2= MX\TRW5ITVJ?
G-402 MlfwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MknjTWM2OD1{MD61N|M1KM7:TR?= M1jROHNCVkeHUh?=
HL-60 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTJzLkG2NVMh|ryP Ml;PV2FPT0WU
A2058 M13PN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\qTWM2OD1{MT60OFc4KM7:TR?= NGHy[5RUSU6JRWK=
CHP-212 M1S1U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NILNVZFKSzVyPUKxMlkxPTFizszN M2jzSHNCVkeHUh?=
KY821 NFz3eJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1vReWlEPTB;MkGuPVc2KM7:TR?= NEjlcZlUSU6JRWK=
TYK-nu M1vq[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFX3ZZhKSzVyPUKyMlA3PTFizszN M3nIWnNCVkeHUh?=
JVM-2 NWXabJVYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mkf3TWM2OD1{Mj6yPVg{KM7:TR?= NEToRZNUSU6JRWK=
KU812 M4nLWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M33FVmlEPTB;MkKuO|MyOiEQvF2= NVPIe4gzW0GQR1XS
MKN28 M{TDSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTJ{LkmwNVUh|ryP MkPhV2FPT0WU
ECC10 M2PEXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HPZmlEPTB;MkOuO|QyKM7:TR?= NXrESHMxW0GQR1XS
BHT-101 MorKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnfuTWM2OD1{ND6wNFA5KM7:TR?= M2m4bnNCVkeHUh?=
DU-4475 NXXkPYlGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnXlTWM2OD1{ND6zN|M4KM7:TR?= NXvIdoZ7W0GQR1XS
769-P MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW[zUGxPUUN3ME2yOE45PDZ4IN88US=> M2HOOXNCVkeHUh?=
HEC-1 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmLiTWM2OD1{NT60OFUh|ryP Moi4V2FPT0WU
MOLT-13 M1GwVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTJ3LkWzN|Eh|ryP NVu0XlA2W0GQR1XS
8505C MkXRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTJ4LkS5O|ch|ryP MmDGV2FPT0WU
GB-1 M4HNNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvJZYNKSzVyPUK2MlcyPzZizszN M{C2UHNCVkeHUh?=
SF126 NYLzNXdCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVLTR|duUUN3ME2yOk44PjR6IN88US=> NELzWYFUSU6JRWK=
A4-Fuk NIjRNpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGr4RmpKSzVyPUK3MlEzPzFizszN M122ZXNCVkeHUh?=
OVCAR-8 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{PjTmlEPTB;MkeuNVU{QSEQvF2= M1\kUnNCVkeHUh?=
NCI-H1304 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1LnTWlEPTB;MkeuOVQh|ryP MWTTRW5ITVJ?
GR-ST MmjHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlT0TWM2OD1{OD6wOFch|ryP MXfTRW5ITVJ?
G-401 MnPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTJ6LkWwPVYh|ryP M{LGTHNCVkeHUh?=
LXF-289 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\3TI5KSzVyPUK4MlU3PTFizszN MU\TRW5ITVJ?
DBTRG-05MG MlLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\lW2lEPTB;MkiuPVIxPCEQvF2= M3v1bnNCVkeHUh?=
YKG-1 M4rydWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTJ7Lki2PEDPxE1? MVLTRW5ITVJ?
GAMG MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHvDNFFKSzVyPUK5Mlk6OyEQvF2= NX[3OIdNW0GQR1XS
HCT-116 NEi0WW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDlTWM2OD1|MD6wOVQ5KM7:TR?= NUjtWWtXW0GQR1XS
S-117 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLWSZFKSzVyPUOxMlIzPTdizszN M3PKZ3NCVkeHUh?=
NCI-H1693 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3z0V2lEPTB;M{OuOlU1OiEQvF2= MUfTRW5ITVJ?
A427 NIfYcVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4DpUGlEPTB;M{OuPVk4PiEQvF2= NUHN[HNiW0GQR1XS
HT-29 NFHiNpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDHTWM2OD1|ND62NFMzKM7:TR?= MUXTRW5ITVJ?
P12-ICHIKAWA M2LPOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHPtNpVKSzVyPUO0Mlc1QTFizszN MmL1V2FPT0WU
CAL-51 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWDxW|ZFUUN3ME2zOU4xPzB7IN88US=> MYHTRW5ITVJ?
Ramos-2G6-4C10 NUnCU25bT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlu5TWM2OD1|NT6yOFI2KM7:TR?= MVTTRW5ITVJ?
SCH NVHoN3BnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEL4VINKSzVyPUO2MlQyPzRizszN NVn3O4p6W0GQR1XS
SK-MEL-24 MnvyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTN4LkmwOFQh|ryP NIPOPGJUSU6JRWK=
SW1573 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTN6LkeyNVYh|ryP M4jRNHNCVkeHUh?=
BALL-1 NVLOeGxuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jDeWlEPTB;M{muNlEzQSEQvF2= M1Xie3NCVkeHUh?=
BE-13 M4LQTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn6xTWM2OD1|OT6zNlkh|ryP NIGyfmdUSU6JRWK=
GI-1 NYPDd5pST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmP4TWM2OD1|OT64OlQ4KM7:TR?= M2LueHNCVkeHUh?=
GOTO MkTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTN7LkmxN|kh|ryP NVTzbZo1W0GQR1XS
A673 M4O4XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFrUWGhKSzVyPUSxMlA{PDNizszN MYTTRW5ITVJ?
KG-1 NIThe|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHSWVVKSzVyPUSzMlM6PCEQvF2= MXnTRW5ITVJ?
GP5d MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDITWM2OD12ND6wOlY3KM7:TR?= M1P4THNCVkeHUh?=
MFM-223 NUjRdIc5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTR2LkGyNlgh|ryP M2jzcnNCVkeHUh?=
OAW-42 NYHm[VVnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGWz[lNKSzVyPUS0MlI3PDNizszN MlnnV2FPT0WU
C8166 NXG2fpkyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTR3LkC4NlIh|ryP NF7MSZlUSU6JRWK=
LU-99A Mo[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4jmcGlEPTB;NE[uNVMzOiEQvF2= MWLTRW5ITVJ?
NCI-H23 M2OzW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTR4LkG3PFUh|ryP M{\EWnNCVkeHUh?=
HO-1-N-1 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;GWndOUUN3ME20O{4xQTl6IN88US=> Ml3qV2FPT0WU
A3-KAW M2f4UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml3lTWM2OD12Nz6xNFA4KM7:TR?= Mn\zV2FPT0WU
CGTH-W-1 M4XEUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWfJR|UxRTR5LkWwOlkh|ryP NUS5O4VRW0GQR1XS
DJM-1 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLmOWhKSzVyPUS3MlU1OTNizszN MlO0V2FPT0WU
A101D NWHodox2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTR5Lk[zOVch|ryP NUXtXHk3W0GQR1XS
BB30-HNC MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYHHW2JmUUN3ME20PE4{ODd{IN88US=> MlTJV2FPT0WU
T98G MofwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4HufGlEPTB;NEiuOFY{OyEQvF2= NILEXXRUSU6JRWK=
NCI-H1573 NWnPcY5yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\4TWM2OD12OT60OFYzKM7:TR?= MWHTRW5ITVJ?
MEG-01 NXX6UFVFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTR7Lke0NVEh|ryP NX;M[IJPW0GQR1XS
WM-115 M1frSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoHwTWM2OD12OT65NlIzKM7:TR?= NIXyV3FUSU6JRWK=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western Blot
DR5/CHOP; 

PubMed: 25531448     


(A) U87 GBM cells were treated with Olaparib (10 µM) for the indicated time points, subjected to immunoblotting and analyzed for the expression of DR5. B-D) U87 (B), U373 (C) and LN229 GBM cells (D) were treated with increasing concentrations of Olaparib (µM) for 7 hours, subjected to immunoblotting and analyzed for the expression of CHOP and DR5. E–F) MDA-MB-468 (E) and MDA-MB-436 (F) were treated with increasing concentrations (µM) of Olaparib for 7 hours, harvested for immunoblotting and analyzed for the expression of DR5.

γH2AX/H2AX; 

PubMed: 22933245     


FK866 exacerbates levels of γH2AX caused by olaparib. CAL51 cells were exposed to FK866 and/or olaparib for 48 h and cell lysates generated and immunoblotted for total and γH2AX.

pATM; 

PubMed: 27686740     


(C) Western blot analysis in HN9-cisR cells according to changes in olaparib doses. Olaparib induced pATM and 53BP1 activation in a dose-dependent manner in HN9-cisR cells. 

53BP1; 

PubMed: 27686740     


(C) Western blot analysis in HN9-cisR cells according to changes in olaparib doses. Olaparib induced pATM and 53BP1 activation in a dose-dependent manner in HN9-cisR cells. 

NF-kB; 

PubMed: 27686740     


(C) Western blot analysis in HN9-cisR cells according to changes in olaparib doses. Olaparib induced pATM and 53BP1 activation in a dose-dependent manner in HN9-cisR cells. 

pS6/S6; 

PubMed: 24831086     


HCC1937 cells (BRCA1-inactive) were treated with 10 nM olaparib with indicated times. Whole-cell lysates were prepared and analyzed by Western blotting with the indicated antibodies. 

25531448 22933245 27686740 24831086
Immunofluorescence
DNA damage; 

PubMed: 27686740     


(A) A comet assay and (B) γH2AX immunofluorescence assay were performed 72 h after olaparib treatment to identify DNA damage. A relatively higher level of DNA damage was observed in HN9-cisR cells; however, olaparib also induced slight DNA damage in olaparib-resistant HN4-cisR cells. Magnification: × 100 (comet assay); × 400 (γH2AX).

γH2AX; 

PubMed: 28069876     


Representative images of immunofluorescence (IF) staining for γH2AX in 22RV1 cells treated with of BI2536 (5 nM), Olaparib (10 µM) or both for 24 h. 22RV1 cells (1 × 105) were plated in 6-well plates on day 0 and then treated with BI2536, Olaparib or both for 24 h.

27686740 28069876
Growth inhibition assay
Cell viability ; 

PubMed: 25531448     


A-D): U87 (A), U373 (B), LN229 (C) and MDA-MB-468 (D) cells were treated with suboptimal dosages of TRAIL (A: 100 ng/ml, B: 25 ng/ml, C: TRAIL 200 ng/ml, D: 10 ng/ml), Olaparib (A–C: 10 µM, D: 5 µM) or the combination of both reagents for 48 hours. Thereafter, MTT assays were performed to determine cellular viability.

25531448
ELISA
IL-8; 

PubMed: 28456021     


ELISA measuring PAR levels in Akata-EBV cells. Cells were treated with 2.5 μM olaparib for 24 h to inhibit PARP activity. Data are shown as pg of PAR per μg of protein. 

GLP-1; 

PubMed: 29392078     


Olaparib enhances promotes GLP-1 secretion in NCI-H716 cells Cells were stimulated for 30 minutes with or without 16 mM glucose. GLP-1 was measured by ELISA. Bars represent the mean of three independent experiments normalized to the control. Error bars indicate standard deviation. Statistical analyses were performed by two-tailed Student’s t-test and significance is denoted by asterisks where *P<0.05.

28456021 29392078
In vivo Combining with temozolomide, Olaparib (10 mg/kg, p.o.) significantly suppresses tumor growth in SW620 xenografts. [1] Olaparib shows great response to Brca1-/-;p53-/- mammary tumors (50 mg/kg i.p. per day), while no responses to HR-deficient Ecad-/-;p53-/- mammary tumors. Olaparib even does not show dose-limiting toxicity in tumor-bearing mice. [3] Olaparib has been used to treat with BRCA mutated tumors, such as ovarian, breast and prostate cancers. Moreover, Olaparib shows selectively inhibition to ATM (Ataxia Telangiectasia Mutated)-deficient tumor cells, which indicates to be a potential agent for treating ATM mutant lymphoid tumors. [4]

Protocol

Kinase Assay:

[1]

+ Expand

FlashPlate assay (96-well screening assay):

To columns 1 through 10, 1 μL of Olaparib (in DMSO) is added, and 1 μL DMSO only is added to the positive (POS) and negative (NEG) control wells (columns 11 and 12, respectively) of a pretreated FlashPlate. PARP-1 is diluted 1:40 in buffer (buffer B: 10% glycerol (v/v), 25 mM HEPES, 12.5 mM MgCl2,50 mM KCl, 1 mM DTT, 0.01% NP-40 (v/v), pH 7.6) and 40 μL added to all 96 wells (final PARP-1 concentration in the assay is ~1 ng/μL). The plate is sealed and shaken at RT for 15 min. Following this, 10 μL of positive reaction mix (0.2 ng/μL of double-stranded oligonucleotide [M3/M4] DNA per well, 5 μM of NAD+ final assay concentration, and 0.075 μCi 3H-NAD+ per well) is added to the appropriate wells (columns 1-11). The negative reaction mix, lacking the DNA oligonucleotide, is added to column 12 (with the mean negative control value used as the background). The plate is resealed and shaken for a further 60 min at RT to allow the reaction to continue. Then, 50 μL of ice-cold acetic acid (30%) is added to each well to stop the reaction, and the plate is sealed and shaken for a further 60 min at RT. Tritiated signal bound to the FlashPlate is then determined in counts per minute (CPM) using the TopCount plate reader.
Cell Research:

[1]

+ Expand
  • Cell lines: Breast cancer cell lines including SW620 colon, A2780 ovarian, HCC1937, Hs578T, MDA-MB-231, MDA-MB-436, and T47D
  • Concentrations: 1-300 nM
  • Incubation Time: 7-14 days
  • Method:

    The cytotoxicity of Olaparib is measured by clonogenic assay. Olaparib is dissolved in DMSO and diluted by culture media before use. The cells are seeded in six well plates and left to attach overnight. Then Olaparib is added at various concentrations and the cells are incubated for 7-14 days. After that the surviving colonies are counted for calculating the IC50.


    (Only for Reference)
Animal Research:

[3]

+ Expand
  • Animal Models: Brca1-/-;p53-/- mammary tumors are generated in K14cre;Brca1F/F;p53F/F mice.
  • Formulation: 50 mg/mL stocks in DMSO with 10% 2-hydroxyl-propyl-β-cyclodextrine/PBS
  • Dosages: 50 mg/kg
  • Administration: Administered via i.p. injection at 10 μL/g of body weight
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 86 mg/mL warmed (197.94 mM)
Water 0.002 mg/mL (0.0 mM)
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
4% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 434.46
Formula

C24H23FN4O3

CAS No. 763113-22-0
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03561870 Not yet recruiting Recurrent IDH|Mutant High Grade Glioma Hospices Civils de Lyon December 1 2019 Phase 2
NCT03561870 Not yet recruiting Recurrent IDH|Mutant High Grade Glioma Hospices Civils de Lyon December 1 2019 Phase 2
NCT03741426 Not yet recruiting Renal Cell Cancer CCTU- Cancer Theme|University of Cambridge|AstraZeneca|Cancer Research UK|Cambridge University Hospitals NHS Foundation Trust July 25 2019 Phase 2
NCT03741426 Not yet recruiting Renal Cell Cancer CCTU- Cancer Theme|University of Cambridge|AstraZeneca|Cancer Research UK|Cambridge University Hospitals NHS Foundation Trust July 25 2019 Phase 2
NCT03880019 Not yet recruiting Stage III Uterine Corpus Leiomyosarcoma AJCC v8|Stage IIIA Uterine Corpus Leiomyosarcoma AJCC v8|Stage IIIB Uterine Corpus Leiomyosarcoma AJCC v8|Stage IIIC Uterine Corpus Leiomyosarcoma AJCC v8|Stage IV Uterine Corpus Leiomyosarcoma AJCC v8|Stage IVA Uterine Corpus Leiomyosarcoma AJCC v8|Stage IVB Uterine Corpus Leiomyosarcoma AJCC v8 National Cancer Institute (NCI) June 7 2019 Phase 2
NCT03842228 Not yet recruiting Advanced Malignant Solid Neoplasm|ARID1A Gene Mutation|ATM Gene Mutation|ATRX Gene Mutation|BARD1 Gene Mutation|BRCA1 Gene Mutation|BRCA2 Gene Mutation|BRIP1 Gene Mutation|CDK12 Gene Mutation|CHEK1 Gene Mutation|CHEK2 Gene Mutation|FANCA Gene Mutation|FANCL Gene Mutation|Metastatic Malignant Solid Neoplasm|MRE11 Gene Mutation|MSH2 Gene Mutation|PALB2 Gene Mutation|PARP1 Gene Mutation|PIK3CA Gene Mutation|POLD1 Gene Mutation|PPP2R2A Gene Mutation|PTEN Gene Mutation|RAD51B Gene Mutation|RAD51C Gene Mutation|RAD51D Gene Mutation|RAD54L Gene Mutation|Unresectable Malignant Solid Neoplasm|XRCC2 Gene Mutation National Cancer Institute (NCI) June 10 2019 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    How to prepare the solution of the compound (S1060) for in vivo study?

  • Answer:

    We recommend the following formulation: 4% DMSO+30% PEG300+ 66%H2O. It is a clear solution and can be used for IP injection.

  • Question 2:

    I saw that the solubility of the compound for in vivo on the website had been changed, why the change has been made?

  • Answer:

    For the formulation for in vivo, the compound dissolving in 15% Captisol (former solubility) is a suspension, and it is fine for oral gavage. And now, dissolving in 4% DMSO+30% PEG 300+ddH2O is a clear solution, and is for injection.

  • Question 3:

    How long can the chemical compound be stable in DMEM at 4 °C?

  • Answer:

    The compound is stable in DMEM at 4 degree for one week.

PARP Signaling Pathway Map

PARP Inhibitors with Unique Features

Related PARP Products5

Tags: buy Olaparib (AZD2281, Ku-0059436) | Olaparib (AZD2281, Ku-0059436) supplier | purchase Olaparib (AZD2281, Ku-0059436) | Olaparib (AZD2281, Ku-0059436) cost | Olaparib (AZD2281, Ku-0059436) manufacturer | order Olaparib (AZD2281, Ku-0059436) | Olaparib (AZD2281, Ku-0059436) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID